SPECT imaging agents for serotonin transporters
View Patent ↗The present invention is directed to compounds of Formula (I) or pharmaceutically acceptable salts thereof; wherein X is hydrogen, Cl, Br, I, NO 2 , NR 3 R 4 or —L—Ch; Y is hydrogen, —CH 2 OR 5 , —CH 2 NCH 3 R 1 , NO 2 , NR 3 R 4 or —L—Ch; Y′ is hydrogen, —CH 2 OH 5 , —CH 2 NCH 3 R 1 , NO 2 , NR 3 R 4 OR —L—Ch; provided that at least one of the Y or Y′ is —CH 2 NCH 3 R 1 ; Z is S, O, NR 6 CR 7 R 8 , C(O) or —C(═CR 7 R 8 )-; A is hydrogen, Cl, I, Br or —L—Ch; R 1 is hydrogen, C 1 -C 5 alkyl, C 3 -C 8 cycloalkyl C 1-5 alkylcarbonyl, (C 3 -C 8 cycloalkyl) carbonyl, pnenyl, benzyl, naphthyl, naphthylmethyl or L—Ch; R 2 is hydrogen or methyl; and R 3 -R 8 are as defined herein. Radiolabeled compounds of the invention are useful as selective serotonin transporter (SERT) imaging agents for single photon emission tomography (SPECT). As such the compounds are useful for studying the underlying pharmacology and interaction of specific serotinin reuptake site inhibitors (SSRI), commonly used antidepressants, at the SERT sites in the human brain. Certain compounds of the invention, including IDAM (5-iodo-2[[2-2-[(dimethylamino)methyl]phenyl]thio]benzylalcohol) display affinity to SERT sites and show more high selectively for SERT over NET and DAT.
1. A compound of Formula I:
or a pharmaceutically acceptable salt thereof; wherein
X is hydrogen, Cl, Br, I, NO 2 , or NR 3 R 4 ;
Y is hydrogen, —CH 2 OR 5 , —CH 2 NCH 3 R 1 , NO 2 , or NR 3 R 4 ;
Y′ is hydrogen, —CH 2 OR 5 , —CH 2 NCH 3 R 1 , NO 2 , or NR 3 R 4 ; provided that at least one of the Y or Y′ is —CH 2 NCH 3 R 1 ;
Z is S, or O;
A is hydrogen, Cl, I, or Br;
R 1 is hydrogen, C 1 -C 5 alkyl, C 3 -C 8 cycloalkyl, C 1-5 alkylcarbonyl, (C 3 -C 8 cycloalkyl)carbonyl, phenyl, benzyl, naphthyl, or naphthylmethyl;
R 2 is hydrogen or methyl;
R 3 and R 4 are independently hydrogen, hydroxy, C 1 -C 5 alkyl, C 3 -C 8 cycloalkyl, C 1 - 5 alkylcarbonyl, (C 3 -C 8 cycloalkyl)carbonyl, phenyl, benzyl, naphthyl, or naphthylmethyl;
R 5 is hydrogen, C 1 -C 5 alkyl, C 3 -C 8 cycloalkyl, C 1-5 alkylcarbonyl, (C 3 -C 8 cycloalkyl)carbonyl, phenyl, benzyl, naphthyl, or naphthylmethyl;
R 6 is hydrogen, C 1 -C 5 alkyl, C 3 -C 8 cycloalkyl, C 1-5 alkylcarbonyl, (C 3 -C 8 cycloalkyl)carbonyl, phenyl, benzyl, naphthyl, or naphthylmethyl; and
R 7 and R 8 are independently hydrogen, C 1 -C 5 alkyl or chloro;
with the proviso that one or both of X or A is selected from the group consisting of 123 I, 131 I, 125 I, 77 Br and 76 Br.
2. A compound of claim 1 , wherein
X is selected from the group consisting of 123 I, 131 I, 125 I, 77 Br and 76 Br;
Y is —CH 2 OR 5 , NO 2 or NR 3 R 4 ;
A is hydrogen;
R 1 is hydrogen, C 1 -C 5 alkyl, C 3 -C 8 cycloalkyl, C 1-5 alkylcarbonyl, (C 3 -C 8 cycloalkyl)carbonyl, phenyl, benzyl, naphthyl or naphthylmethyl;
R 2 is hydrogen or methyl;
R 3 and R 4 are independently hydrogen, hydroxy, C 1 -C 5 alkyl, C 3 -C 8 cycloalkyl, C 1-5 alkylcarbonyl, (C 3 -C 8 cycloalkyl)carbonyl, phenyl, benzyl, naphthyl or naphthylmethyl;
R 5 is hydrogen, C 1 -C 5 alkyl, C 3 -C 8 cycloalkyl, C 1-5 alkylcarbonyl, (C 3 -C 8 cycloalkyl)carbonyl, phenyl, benzyl, naphthyl or naphthylmethyl;
R 6 is hydrogen, C 1 -C 5 alkyl, C 3 -C 8 cycloalkyl, C 1-5 alkylcarbonyl, (C 3 -C 8 cycloalkyl)carbonyl, phenyl, benzyl, naphthyl or naphthylmethyl; and
R 7 and R 8 are independently hydrogen, C 1 -C 5 alkyl or chloro.
3. A compound of claim 1 , wherein
X is hydrogen, Cl, Br, I, NO 2 or NR 3 R 4 ;
Y is —CH 2 OR 5 , NO 2 or NR 3 R 4 ;
A is selected from the group consisting of 123 I, 131 I, 125 I, 77 Br and 76 Br;
R 1 is hydrogen, C 1 -C 5 alkyl, C 3 -C 8 cycloalkyl, C 1-5 alkylcarbonyl, (C 3 -C 8 cycloalkyl)carbonyl, phenyl, benzyl, naphthyl or naphthylmethyl;
R 2 is hydrogen or methyl;
R 3 and R 4 are independently hydrogen, hydroxy, C 1 -C 5 alkyl, C 3 -C 8 cycloalkyl, C 1-5 alkylcarbonyl, (C 3 -C 8 cycloalkyl)carbonyl, phenyl, benzyl, naphthyl or naphthylmethyl;
R 5 is hydrogen, C 1 -C 5 alkyl, C 3 -C 8 cycloalkyl, C 1-5 alkylcarbonyl, (C 3 -C 8 cycloalkyl)carbonyl, phenyl, benzyl, naphthyl or naphthylmethyl;
R 6 is hydrogen, C 1 -C 5 alkyl, C 3 -C 8 cycloalkyl, C 1-5 alkylcarbonyl, (C 3 -C 8 cycloalkyl)carbonyl, phenyl, benzyl, naphthyl or naphthylmethyl; and
R 7 and R 8 are independently hydrogen, C 1 -C 5 alkyl or chloro.
4. A compound of claim 2 , wherein X is a radioactive isotope selected from the group consisting of 123 I, 131 I, and 125 I.
5. A compound of claim 4 , wherein X is 123 I.
6. A compound of claim 3 , wherein A is a radioactive isotope selected from the group consisting of 123 I, 131 I, and 125 I.
7. A compound of claim 6 , wherein A is 123 I.
8. A compound of claim 1 , having the general formula:
or
or a pharmaceutically acceptable salt thereof, where
X is selected from the group consisting of 123 I, 131 I, 125 I, 77 Br and 76 Br;
Y, Z and R 1 and R 2 are as defined as in claim 1 .
9. A compound of claim 8 , wherein:
Y is —CH 2 OH; —CH 2 OCH 3 ; —NHR 4 , where R 4 is hydrogen, hydroxy or C 1-5 alkyl; —NO 2 ; or —CH 2 OC(O)CH 3 ; and
R 1 is methyl.
10. A compound of claim 9 , wherein X is selected from the group consisting of 123 I, 131 I, and 121 I.
11. A compound of claim 8 , wherein:
Y is —CH 2 OH; —CH 2 OCH 3 ; —NH 2 , or —OH;
Z is S; and
R 1 is hydrogen or methyl.
12. A compound of claim 8 , having the formula VIII, wherein:
X is selected from the group consisting of 123 I, 131 I and 125 I;
Y is —NH 2 ;
Z is —S—; and
R 1 is methyl.
13. A compound of claim 8 , having the formula VIII, wherein:
X is selected from the group consisting of 123 I, 131 I and 125 I;
Y is —CH 2 OH;
Z is —S—; and
R 1 is methyl.